Recovery Act Limited Competition: Comparative Effectiveness Research on Upper Endoscopy in Gastroesophageal Reflux Disease, Eradication Methods for Methicillin Resistant Staphylococcus aureus and Dementia Detection and Management Strategies (RC4)

archived

Purpose. This NIH Funding Opportunity Announcement (FOA), supported by funds provided to the NIH under the American Recovery and Reinvestment Act of 2009 (Recovery Act or ARRA), Public Law 111-5, invites applications to conduct preliminary comparative effectiveness research (CER) projects in targeted, high-priority areas in which such efforts have been lacking. (For this FOA, applications should be thought of as large pilot or preliminary studies rather than definitive trials.) For the purposes of this FOA, the definition of comparative effectiveness research will adhere to that adopted by the Federal Coordinating Council given at http://www.hhs.gov/recovery/programs/cer/execsummary.html. Mechanism of Support. This FOA will use the ARRA-specific NIH mechanism RC4. Funds Available and Anticipated Number of Awards. The NIH intends to commit $15,000,000 for use under this FOA, $5,000,000 in each of the 3 targeted areas. We anticipate that 4-6 awards will be made in each area for fiscal year 2010, pending the number and quality of applications and availability of funds. Budget and Project Period. Total costs are limited to a cumulative total of $1,250,000 throughout the grant period. The total project period for an application submitted in response to this funding opportunity may not exceed three years.

High